Methylenedioxybenzylamphetamine
From Wikipedia, the free encyclopedia
(Redirected from MDBZ)
 |
|
| Names | |
|---|---|
| IUPAC name
1-(1,3-benzodioxol-5-yl)-N-benzylpropan-2-amine
|
|
| Identifiers | |
65033-29-6  |
|
| Jmol 3D model | Interactive image |
| UNII | QR8242661A  |
|
|
| Properties | |
| C17H19NO2 | |
| Molar mass | 269.343 g/mol |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
 verify (what is ?) |
|
| Infobox references | |
MDBZ, or 3,4-methylenedioxy-N-benzylamphetamine, is a lesser-known psychedelic drug. It is the N-benzyl derivative of MDA. MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown. MDBZ produces few to no effects. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.
In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to 3,4-methylenedioxy-N-benzylamphetamine.[1]
See also[edit]
References[edit]
External links[edit]
 |
This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
